基石藥業-B(02616.HK)獲納入恆生綜合指數的成份股
格隆匯8月20日丨基石藥業-B(02616.HK)宣佈,公司已獲恆生指數有限公司納入恆生綜合指數的成份股,並將於2021年9月6日生效。
恆生綜合指數涵蓋在香港聯合交易所有限公司主機板上市證券總市值最高的95%,提供了一項全面的香港市場指標。恆生綜合指數採用流通市值加權法計算,可以用作發行指數基金、互惠基金及表現量度基準。基石藥業被納入恆生綜合指數標誌着公司已符合了被納入港股通交易的標準,港股通是香港與中國大陸廣大資本市場投資者之間的股票買賣與投資的管道。
董事會認為,公司被納入市場基準指數代表了資本市場對集團經營業績和增長前景的認可。董事會認為,公司獲納入市場基準指數將有助於擴闊公司的股東基礎及增加股份流動性,從而實現公司的投資價值及提高公司在資本市場的聲譽及集團知名度。
自2015年成立以來,基石藥業一直專注於中國高發癌種並開發了多種候選藥物,為患者帶來變革性療法,併成為業內少數能夠在全球範圍內推進商業化進程的公司之一。2021年,基石藥業已成功在中國大陸和台灣地區上市兩款產品,預計今年還將獲得多項新藥上市申請的批准。目前,公司正與合作伙伴輝瑞和EQRx緊密合作,儘快推進包括舒格利單抗在內的腫瘤免疫產品在中國大陸及海外的臨牀開發及商業化進程,從而實現產品整體價值的最大化。此次入選恆生綜合指數,將進一步提升公司的市場關注度,擴大投資者羣體,有利於促進公司長期可持續性發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.